Get the Stockscreener App
7.76
1.91%
0.16
Immunitybio Inc stock is traded at $7.76, with a volume of 4.64M.
It is up +1.91% in the last 24 hours and down -5.78% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$7.60
Open:
$7.71
24h Volume:
4.64M
Relative Volume:
0.38
Market Cap:
$8.23B
Revenue:
$140.98M
Net Income/Loss:
$-854.60M
P/E Ratio:
-9.0867
EPS:
-0.854
Net Cash Flow:
$-299.31M
1W Performance:
+6.83%
1M Performance:
-5.78%
6M Performance:
+16.99%
1Y Performance:
+213.56%
1-Day Range:
$7.60
$7.82
1-Week Range:
$7.185
$7.82
52-Week Range:
$1.95
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.765 | 8.05B | 140.98M | -854.60M | -299.31M | -0.854 |
VRTX
Vertex Pharmaceuticals Inc
|
525.14 | 134.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
798.04 | 82.06B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
875.76 | 54.10B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.94 | 44.06B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.44 | 40.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
ImmunityBio, Inc. (IBRX) options chain - Yahoo Finance UK
IBRX Stock In Spotlight: ImmunityBio To Unveil Fresh Anktiva And BCG Data Next Week - Stocktwits
IBRX Stock Climbs Overnight: ImmunityBio Declares ‘All Systems Go’ For Dunkirk Anktiva Manufacturing Push - Stocktwits
ImmunityBio, Inc. • Robinhood Token (IBRX) Price Prediction for 2026 to 2031 - Bybit
Archer Aviation (NYSE: ACHR) Among IBRX, JOBY, SCKT Leading Technology Stocks – Plus More in Focus - FinancialContent
ImmunityBio (IBRX) Tests Its Valuation After UAE ANKTIVA Approval Expands Its Reach - Sahm
ImmunityBio Names Former World Bank President Jim Yong Kim Vice Chairman - citybiz
ImmunityBio appoints Jim Yong Kim as vice chairman - Investing.com
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman - Business Wire
Why ImmunityBio (IBRX) Is Up 6.6% After ANKTIVA’s UAE Expansion and Mixed Q2 Results – And What's Next - webull.com
ImmunityBio Founder Dr. Patrick Soon-Shiong to Speak at Milken In - The National Law Review
Analysts Have Been Trimming Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target After Its Latest Report - 富途牛牛
ImmunityBio (IBRX) Stock Looks Rich On Sales But Strong On Returns - Yahoo Finance
ImmunityBio (IBRX) Stock May Trade At A Premium To Fair Value - Sahm
The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses - Yahoo Finance
ImmunityBio (IBRX) group led by Soon-Shiong holds 64.8% stake - Stock Titan
Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright - MarketBeat
IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales - Stocktwits
IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake - Yahoo Finance
HC Wainwright Increases Earnings Estimates for ImmunityBio - MarketBeat
ImmunityBio | 10-Q: Q2 2026 Earnings Report - Moomoo
ImmunityBio Releases Q2 2026 Financial Results - AlphaStreet
ImmunityBio (NASDAQ:IBRX) Posts Earnings Results, Misses Estimates By $0.14 EPS - MarketBeat
ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings - MarketBeat
ImmunityBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc - The National Law Review
Immunitybio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Immunitybio Inc earnings missed by $0.14, revenue topped estimates - Investing.com
Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M - marketscreener.com
ImmunityBio 2Q 2026: Revenue $51.24M, EPS ($0.22) — 10-Q Summary - TradingView
[10-Q] ImmunityBio, Inc. Quarterly Earnings Report - Stock Titan
ImmunityBio: Q2 Earnings Snapshot - Barchart.com
ImmunityBio posts Q2 2026 product revenue $50.7M; H1 revenue $94.8M, cash $357.4M - TradingView
Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX) - Stock Titan
ImmunityBio, Inc. (IBRX) Q2 2026 Earnings - 24/7 Wall St.
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million - Business Wire
ImmunityBio, Inc. (IBRX) Stock Analysis: Assessing a 78% Potential Upside in Cutting-Edge Immunotherapy - DirectorsTalk Interviews
Weekly Recap: U.S. papillary-only label expansion and UAE ANKTIVA approval - TradingView
ImmunityBio, Inc. (IBRX) Options Chain - Yahoo! Finance Canada
Arete Wealth Advisors LLC Makes New Investment in ImmunityBio, Inc. $IBRX - MarketBeat
ImmunityBio receives UAE marketing authorizations for ANKTIVA across NMIBC and NSCLC - TradingView
ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug - Benzinga
IBRX Stock Jumps Overnight: UAE Grants Anktiva Broadest Approval Yet After Founder’s ‘July Birthday News’ Tease - TradingView
UAE Gives ANKTIVA World’s First Approval Across BCG-Unresponsive Bladder Cancer - Stock Titan
ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Gros - The National Law Review
IBRX|Immunitybio Inc|Price:7.000|Chg%:-0.100 - TradingKey
PATRICK SOON-SHIONG - Orange County Business Journal
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
IBRX Stock Rises Overnight: Retail Traders Hunt For Global Expansion Clues Ahead Of Biotech Conference - Yahoo Finance
ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All' - Stocktwits
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cohen Cheryl | Director |
Jul 02 '26 |
Sale |
9.50 |
131,210 |
1,246,941 |
125,386 |
| Selecky Christobel | Director |
Jul 01 '26 |
Option Exercise |
2.99 |
159,478 |
476,489 |
159,478 |
| Selecky Christobel | Director |
Jul 01 '26 |
Sale |
9.02 |
159,478 |
1,439,066 |
0 |
4.90%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):